The injection of GCSF into the AML-treated group (AML+GCSF) reversed the abnormal levels of (Il-10 and Il-6) to normal levels compared to CT 2 weeks post-treatment (Figure 9A,B). This evidence concerns the gene IL6 and acute myeloid leukemia.